Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 214

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Enhanced activity of a hydrogen sulphide‐releasing derivative of mesalamine (ATB‐429) in a mouse model of colitis

Open access
Fiorucci, S, Orlandi, S, Mencarelli, A, Caliendo, G, Santagada, V, Distrutti, E, Santucci, L, Cirino, G, Wallace, J L·2007·British Journal of Pharmacology

Abstract

Background and Purpose: Mesalamine is the first‐line therapy for colitis, but it lacks potency and is only effective for mild‐to‐moderate forms of this disease. Hydrogen sulphide has been shown to be a potent, endogenous anti‐inflammatory substance, modulating leukocyte‐endothelial adhesion and leukocyte migration. The purpose of this study was to determine if an H 2 S‐releasing derivative of mesalamine (ATB‐429) would exhibit increased potency and effectiveness in a mouse model of colitis. Experimental Approach: Colitis was induced in mice with trinitrobenzene sulphonic acid and the effects of ATB‐429 and mesalamine were compared in several treatment regimens. The severity of colitis was determined using several indices, including a disease activity score (comprised of scores for diarrhea, weight loss and fecal blood), colonic myeloperoxidase activity and macroscopic/microscopic scoring of tissue injury. Key Results: Irrespective of the treatment regiment, ATB‐429 was more effective than mesalamine in reducing the severity of colitis. ATB‐429 was particularly effective in reducing granulocyte infiltration into the colonic tissue (by ∼70%), as well as reducing the expression of mRNA for several key proinflammatory cytokines/chemokines (e.g., TNF α, IFN γ). Treatment with ADT‐OH, the H 2 S‐releasing moiety of ATB‐429, did not affect severity of colitis. Conclusions and Implications: ATB‐429 exhibits a marked increase in anti‐inflammatory activity and potency in a murine model of colitis, as compared to mesalamine. These results are consistent with recently described anti‐inflammatory effects of H 2 S. ATB‐429 may represent an attractive alternative to mesalamine for the treatment of inflammatory bowel disease. British Journal of Pharmacology (2007) 150, 996–1002. doi:10.1038/sj.bjp.0707193

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707193

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 214

Metadata

Authors
Fiorucci, S., Orlandi, S., Mencarelli, A., Caliendo, G., Santagada, V, Distrutti, E., Santucci, L., Cirino, G., & Wallace, J. L.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2007-04
Volume
150
Issue
8
Pages
996-1002
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1888068317
Cited by
214
References
2
FWCI
6.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhanced activity of a hydrogen sulphide‐releasing derivative of mesalamine (ATB‐429) in a mouse model of colitis. https://app.cochat.ai/papers/10.1038/sj.bjp.0707193
The paper
Fiorucci, S., Orlandi, S., Mencarelli, A., Caliendo, G., Santagada, V, Distrutti, E., Santucci, L., Cirino, G., & Wallace, J. L. (2007). Enhanced activity of a hydrogen sulphide‐releasing derivative of mesalamine (ATB‐429) in a mouse model of colitis. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0707193

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.